Health Canada authorizes functional claims that the probiotic strain DDS-1® “helps alleviate perceived stress and improve irritable bowel syndrome-related quality of life in adolescents and adults”
The ‘gut-brain axis’ has become one of the most cutting-edge areas of research over the past few years, diving into how the fascinating interplay between the brain, gut and microbiome can impact physical and digestive issues, as well as mental well-being. It is well-known, for example, that people with irritable bowel syndrome (IBS) frequently report feeling sad, embarrassed and self-conscious, which impacts their quality of life and could even limit participation in social activities (1).
Chr. Hansen’s probiotic strain L. acidophilus, DDS-1® is already authorized by Health Canada to help improve abdominal pain severity and symptomology in IBS in adolescents and adults. Now the existing Natural Health Product (NPH) license for the DDS-1® strain in Canada has been amended to include the following gut-brain axis claims:
- Helps alleviate perceived stress in adolescents and adults with irritable bowel syndrome
- Helps to improve irritable bowel syndrome-related quality of life in adolescents and adults
- Helps alleviate perceived stress in conjunction with improving abdominal pain in adolescents and adults with irritable bowel syndrome
- Helps normalize stool consistency of those with irritable bowel syndrome in adolescents and adults.
Quality stamp of the science behind
“We are excited that one of our probiotic strains has received official Canadian health claims relating to the gut-brain axis, putting a quality stamp on the science behind our product and adding credibility to our offering in this emerging field,” says Niklas Larsson, PhD, Head of Scientific Affairs, Chr. Hansen Human Health.
“It will assist consumers in making informed health choices when selecting probiotics and reinforce their confidence that the products are effective, safe and of high quality. Officially registered health claims will drive increased interest in our clinically documented probiotics and their potential benefit in general, both in Canada and other markets,” concludes Linda Neckmar, SVP, Chr. Hansen Human Health.
DDS-1® is a trademark of Chr. Hansen A/S.
This communication is only intended for business-to-business and health care professionals. This communication is not intended for consumers on final consumer goods. Please check your local regulations for acceptable claims in the market.
(1) International Foundation for Functional Gastrointestinal Disorders (IFFGD). IBS patients: Their illness experience and unmet needs. An online study. 2009.
Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for almost 150 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 50,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As one of the world’s most sustainable companies, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.